Welcome to our dedicated page for TEMPRAMED TECHNOLOGIES news (Ticker: TMPTF), a resource for investors and traders seeking the latest updates and insights on TEMPRAMED TECHNOLOGIES stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TEMPRAMED TECHNOLOGIES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TEMPRAMED TECHNOLOGIES's position in the market.
TempraMed Technologies (TMPTF) reported record July 2026 sales of approximately US$522,000 and strong August and year-to-date performance.
August 2026 sales were about US$403,000, the second-highest month in the company’s history. For the eight months ended August 31, 2026, sales reached roughly US$2.07 million, already exceeding full-year 2025 sales of about US$1.8 million. Management expects Q3 2026 sales to be significantly stronger than Q3 2025, citing growing demand for its temperature-protection products and expansion into institutional, pharmacy, distributor and healthcare-system channels. All figures are preliminary and unaudited.
TempraMed (OTCQB: TMPTF) signed a non-binding letter of intent dated July 30, 2026 with CPO Greece for the proposed exclusive distribution of its VIVI Cap™ and VIVI Epi™ injectable medication-protection products in Greece, subject to a definitive agreement.
According to TempraMed, exclusivity would depend on CPO meeting minimum annual purchase obligations and increasing combined VIVI Cap and VIVI Epi purchases by at least 20% year over year. Transfer prices and first-year minimum unit commitments will be finalized in the definitive contract. TempraMed highlights CPO’s long-established Greek pharmacy and healthcare distribution platform and positions the potential agreement as part of a broader strategy of adding and renewing distribution deals outside the USA, including in Panama, Mexico, South Korea, Turkey, Saudi Arabia, Israel, Kuwait, Brazil, Benelux and Greece.
TempraMed (OTCQB: TMPTF) signed a definitive five-year distribution agreement dated August 10, 2026 with Black Olives Company to commercialize a private-label version of VIVI Cap™ in Saudi Arabia. The program targets retail rollout through Nahdi Medical Company, the country’s largest pharmacy chain with more than 1,100 pharmacies.
The distributor must place a firm initial order of 10,000 units, with payment for 60% due after Saudi regulatory clearance and the balance secured by a Letter of Credit. Minimum annual purchase commitments imply approximately US$3.8 million in potential aggregate purchases over five years, subject to regulatory clearance and continued compliance.
TempraMed Technologies (OTCQB: TMPTF) reported that Maccabi Healthcare Services, Israel's second-largest HMO, has exercised its option to extend their existing agreement for an additional year under the same terms. Maccabi serves more than 2.6 million members, through whom TempraMed’s temperature-protection devices for injectable medications, including insulin, GLP‑1 and peptides, are made available.
According to TempraMed, the extension supports ongoing adoption of its patented, battery‑free thermal insulation technology and aligns with its strategy to grow institutional and payer partnerships. The company also disclosed that Nancy Goertzen resigned from its Board of Directors and related committees effective August 19, 2026.
TempraMed Technologies (OTCQB: TMPTF) signed a definitive, exclusive distribution agreement with TEM Consulting International, a Panamanian healthcare logistics specialist, for the distribution and commercialization of TempraMed’s temperature-protection portfolio in Panama. The deal converts a previously announced LOI into a binding commercial relationship and includes fulfillment of the first bulk commercial order.
Under the Agreement, TEM will act as TempraMed’s exclusive distributor, advancing product placement into clinics and pharmacies to expand access for healthcare providers and patients. This supports TempraMed’s strategy to shift toward institutional, healthcare, and pharmacy-based channels and build scalable international distribution infrastructure.
TempraMed (CSE: VIVI, FSE: 9DY; OTC: TMPTF) announced a strategic partnership with Stealth Health, a North American telemedicine platform for longevity and precision wellness. The agreement integrates TempraMed’s VIVI temperature-controlled medication protection products into Stealth Health’s direct-to-patient telemedicine clinic and its enterprise white-label network.
The partnership targets patients using temperature-sensitive medications such as hormones, peptides, GLP-1s, biologics and anti-aging treatments, leveraging TempraMed’s patented, battery-free, space-grade thermal insulation technology. According to TempraMed, Stealth Health’s MSO-based, HIPAA-compliant platform, operational across all 50 U.S. states, provides scalable B2C access and reinforces TempraMed’s strategy to commercialize through clinical and wellness channels, while potentially opening additional global distribution opportunities.
TempraMed Technologies (CSE: VIVI, OTCQB: TMPTF) announced that its common shares have been approved for trading on the OTCQB Venture Market and are now DTC eligible, enabling electronic settlement through the Depository Trust Company. Shares will continue trading on the CSE under VIVI.
According to TempraMed, the OTCQB uplisting and DTC eligibility are expected to enhance trading accessibility for U.S. investors, improve liquidity potential, and broaden visibility among retail and institutional investors. TempraMed develops patented, FDA-registered temperature-controlled medication storage solutions, including VIVI Cap and VIVI Epi, with operations across North America, Europe and Asia.